Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Appellate Hearing In Similac Claim Case Set For Nov. 9

This article was originally published in The Tan Sheet

Executive Summary

Arguments on appeal will be heard Nov. 9 in the Seventh Circuit federal court case Mead Johnson v. Abbott Labs. The case concerns the "1st Choice of Doctors" claim for Abbott's Similac infant formula.

You may also be interested in...



Abbott "1st Choice Of Doctors" Infant Formula Claim "Misleading" - Judge

Abbott Labs is temporarily barred from using the claim "1st choice of doctors" on advertising or labeling for its Similac or other infant brands except for Isomil in a preliminary injunction handed down March 18 by Evansville, Ind. federal court Judge David Hamilton. Mead Johnson (Enfamil) requested the injunction in a suit filed in July ("The Tan Sheet" July 27, 1998, p. 1).

Abbott Ensure vitamin content comparison to multivitamins unfounded -- FTC.

ABBOTT AGREES TO HALT ENSURE UNSUBSTANTIATED "DOCTOR RECOMMENDED" CLAIMS under a proposed settlement with the Federal Trade Commission. The agreement would prohibit the Abbott Park, Ill.-based OTC and nutritional product marketer from claiming in future ads that Ensure is recommended by doctors as a meal replacement and/or supplement for healthy adults without appropriate substantiation, FTC announced Jan. 2. Comments on the proposed settlement will be accepted through March 2.

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS090525

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel